PE22.02 MRI examination of cabotegravir long-acting formulation depot kinetics in healthy adult volunteersE-posterPharmacology/PK and PD studies
PE22.03 Impact of UGT induction by rifampin and rifabutin on cabotegravir long-acting pharmacokinetics for HIV pre-exposure prophylaxis (PrEP) using population pharmacokinetic modeling and simulationE-posterPharmacology/PK and PD studies
OA10.01 Planning for success: generating an early roadmap with global stakeholders for increasing access and uptake of new biomedical prevention products in resource-limited settings: The *Biomedical Prevention Implementation C*ollaborative (BioPIC)Oral Abstract SessionPolicy and advocacy
OA10.02 Pathways to global access for novel HIV prevention technologiesOral Abstract SessionPolicy and advocacy
PE23.01 Identifying regional disparities in access to HIV and sexual health resources for young men who have sex with men in the United States: The iREACH StudyE-posterPolicy and advocacy
PE23.02 Adoption of WHO's HIV retesting policy for HIV-negative women during the breastfeeding period in 10 high HIV-burden African countriesE-posterPolicy and advocacy
PE23.03 Ten years of the AVAC Advocacy Fellows Program: An evaluationE-posterPolicy and advocacy
PE23.04 Pathogen reduction (PR) as an alternative to donor deferral to mitigate the risk of transfusion-transmitted HIVE-posterPolicy and advocacy
PE23.06LB HIV prevention research and development funding trends 2000'2019: investment priorities to fund innovation in a challenging global health landscapeE-posterPolicy and advocacy
PE23.07LB Planning for voluntary medical male circumcision (VMMC) program sustainability: generating evidence to support targeted transition planning in Zambia and Zimbabwe using the VMMC Transition Assessment Dashboard-VTADE-posterPolicy and advocacy
seek-warrow-warrow-eseek-e381 - 390 of 444 items